ライフサイエンスコーパス: alcoholic cirrhosis

1 f the explant (11 alcoholic hepatitis and 33 alcoholic cirrhosis).

2 in human alcoholic fatty livers, but not in alcoholic cirrhosis.

3 ents transplanted for a listing diagnosis of alcoholic cirrhosis.

4 oholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis.

5 s not recommended for patients with advanced alcoholic cirrhosis.

6 ared with placebo, in patients with advanced alcoholic cirrhosis.

7 uccessful in properly selected patients with alcoholic cirrhosis.

8 may occur in severe liver disease including alcoholic cirrhosis.

9 as being associated with the development of alcoholic cirrhosis.

10 ary sclerosing cholangitis (5.2%; P<0.05) or alcoholic cirrhosis (2.0%; P<0.001).

11 Indications included: alcoholic cirrhosis, 52.6%; viral cirrhosis, 21.8%; cryp

12 vely followed-up cohort of 230 patients with alcoholic cirrhosis (AC) using competing risk analyses.

13 n=3854), hepatitis C virus (HCV; n=15,147), alcoholic cirrhosis (AC; n=8940), HCV+alcohol (n=6066),

14 sed cognitive functions in 117 patients with alcoholic cirrhosis and 163 patients with nonalcoholic c

15 ng candidates for liver transplantation with alcoholic cirrhosis and a persistent sobriety thereafter

16 Two patients had alcoholic cirrhosis and dilated cardiomyopathy; one had

17 pressed in a low percentage of patients with alcoholic cirrhosis and do not influence HCC development

18 on was validated in the French patients with alcoholic cirrhosis and hepatocellular carcinoma.

19 to determine the mechanisms of sarcopenia in alcoholic cirrhosis and potential reversal by leucine.

20 26 patients with alcoholic cirrhosis and variceal haemorrhage were studie

21 male patient received a liver transplant for alcoholic cirrhosis and, 6 years later, developed biopsy

22 the explant (46 alcoholic hepatitis and 138 alcoholic cirrhosis) and diagnosis at both listing as we

23 Patients with alcoholic cirrhosis are at higher risk for hepatocellula

24 e therapies for both alcoholic hepatitis and alcoholic cirrhosis are still wanting.

25 As the most common causes, other than alcoholic cirrhosis, are chronic hepatitis B and C infec

26 ith NASH and similar to patients with stable alcoholic cirrhosis but not as elevated as in patients w

27 In patients with advanced alcoholic cirrhosis, colchicine does not reduce overall

28 irrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (group I), NASH, and cryptogenic cir

29 Patients with alcoholic cirrhosis had a better though not statisticall

30 patients with chronic haemolytic anaemia and alcoholic cirrhosis had black pigment GS.

31 Because patients with alcoholic cirrhosis had more severe liver disease (Child

32 rotein (AFP), but its role in the context of alcoholic cirrhosis has never been assessed.

33 Danish patients with alcoholic cirrhosis have a low risk for HCC, and HCC con

34 e therapies for both alcoholic hepatitis and alcoholic cirrhosis have yet to be discovered.

35 nd-stage liver disease, including those with alcoholic cirrhosis, have normal cardiac function on two

36 utophagy in skeletal muscle of patients with alcoholic cirrhosis is acutely reversed by BCAA/LEU.

37 fic biomarkers for early diagnosis of HCC in alcoholic cirrhosis is still warranted.

38 261 prospectively followed-up patients with alcoholic cirrhosis (mean follow-up 65 months).

39 dependent predictor for HCC in patients with alcoholic cirrhosis (odds ratio [OR], 3.2; 95% CI, 1.5-6

40 of liver disease (alcoholic hepatitis versus alcoholic cirrhosis) on the graft and patient survival.

41 ress were assessed in SAH patients (n = 90), alcoholic cirrhosis patients (n = 60), and healthy contr

42 ve protein product) was higher in SAH versus alcoholic cirrhosis patients and healthy controls (P < 0

43 patient survival of alcoholic hepatitis and alcoholic cirrhosis patients were 75% and 73% (P = 0.97)

44 A total of 90 consecutively alcoholic cirrhosis patients, observed between Jun 2013

45 Compared with alcoholic cirrhosis, patients with alcoholic hepatitis h

46 In NASH and alcoholic cirrhosis related HCC patients pre-procedure s

47 f TACE in a cohort of patients with NASH and alcoholic cirrhosis related HCC.

48 mortality starting 1 year after diagnosis of alcoholic cirrhosis through 2009; ratio of HCC-related m

49 than others (P = 0.03), while patients with alcoholic cirrhosis trended toward worse survival than t

50 Six of the 10 patients had alcoholic cirrhosis, two reported regular alcohol consum

51 coholic liver disease and clinically evident alcoholic cirrhosis (unadjusted OR= 2.25, P=1.7 x 10(-10

52 ar-old man with end-stage liver failure from alcoholic cirrhosis underwent orthotopic liver transplan

53 d RB of PMN from patients with decompensated alcoholic cirrhosis was strongly impaired (30%-35% of co

54 Respondents transplanted for alcoholic cirrhosis were less in favor of direct contact

55 ty-nine patients with advanced (Pugh B or C) alcoholic cirrhosis were randomized to receive either co

56 Ninety-nine consecutive patients with alcoholic cirrhosis were referred for liver transplant e

57 Fifty-two patients with decompensated alcoholic cirrhosis were studied, 27 with acute alcoholi

58 herapy is mainly restricted to patients with alcoholic cirrhosis who remain abstinent.

59 tis as first liver decompensation (Group 1), alcoholic cirrhosis with >/=6 months abstinence (Group 2

60 copenia) is a major clinical complication in alcoholic cirrhosis with no effective therapy.

61 uman liver diseases, such as hepatitis C and alcoholic cirrhosis, with an excellent safety profile (b